Le diagnostic repose sur l'évaluation des symptômes cliniques et des tests neurologiques.
DopamineDiagnostic médical
#2
Quels tests sont utilisés pour évaluer la dopamine ?
Des tests d'imagerie cérébrale et des analyses de sang peuvent être utilisés.
Imagerie cérébraleDopamine
#3
Quels symptômes indiquent un traitement dopaminergique ?
Les symptômes incluent la rigidité musculaire, les tremblements et la bradykinésie.
SymptômesDopamine
#4
Comment évaluer l'efficacité des agents dopaminergiques ?
L'efficacité est évaluée par l'amélioration des symptômes cliniques et des tests fonctionnels.
Efficacité thérapeutiqueDopamine
#5
Quels médecins prescrivent des agents dopaminergiques ?
Les neurologues et psychiatres sont les principaux prescripteurs de ces médicaments.
NeurologiePsychiatrie
Symptômes
5
#1
Quels sont les symptômes d'un excès de dopamine ?
Les symptômes incluent l'anxiété, l'agitation, et des comportements compulsifs.
DopamineSymptômes
#2
Comment la dopamine affecte-t-elle l'humeur ?
La dopamine joue un rôle clé dans la régulation de l'humeur et des émotions.
DopamineHumeur
#3
Quels troubles sont liés à un déficit de dopamine ?
Le Parkinson et la dépression sont des troubles souvent associés à un déficit de dopamine.
Maladie de ParkinsonDépression
#4
Quels symptômes sont traités par des agents dopaminergiques ?
Ils traitent des symptômes comme les tremblements, la rigidité et la dépression.
TremblementsRigidité musculaire
#5
Comment la dopamine influence-t-elle la motivation ?
La dopamine est impliquée dans le circuit de la récompense, influençant la motivation.
MotivationDopamine
Prévention
5
#1
Peut-on prévenir les troubles liés à la dopamine ?
Une alimentation équilibrée et l'exercice peuvent aider à maintenir un bon équilibre dopaminergique.
PréventionDopamine
#2
Quels modes de vie favorisent la santé de la dopamine ?
Un sommeil adéquat, la gestion du stress et l'exercice régulier favorisent la santé dopaminergique.
Mode de vieDopamine
#3
Y a-t-il des aliments qui augmentent la dopamine ?
Les aliments riches en tyrosine, comme les bananes et les avocats, peuvent aider.
NutritionDopamine
#4
Comment le stress affecte-t-il la dopamine ?
Le stress chronique peut réduire les niveaux de dopamine et affecter l'humeur.
StressDopamine
#5
Les suppléments peuvent-ils aider la dopamine ?
Certains suppléments, comme la L-tyrosine, peuvent soutenir la production de dopamine.
SupplémentsDopamine
Traitements
5
#1
Quels sont les principaux agents dopaminergiques ?
Les agonistes de la dopamine comme la cabergoline et la bromocriptine sont courants.
Agonistes de la dopamineTraitement
#2
Comment les agents dopaminergiques sont-ils administrés ?
Ils peuvent être administrés par voie orale, injectable ou transdermique.
Administration médicamenteuseDopamine
#3
Quels effets secondaires des agents dopaminergiques ?
Les effets secondaires incluent nausées, vertiges et troubles du sommeil.
Effets secondairesDopamine
#4
Comment ajuster le dosage des agents dopaminergiques ?
Le dosage est ajusté en fonction de la réponse clinique et des effets secondaires.
DosageDopamine
#5
Les agents dopaminergiques sont-ils efficaces pour tous ?
L'efficacité varie selon les individus et les conditions traitées.
Efficacité thérapeutiqueDopamine
Complications
5
#1
Quelles complications peuvent survenir avec les agents dopaminergiques ?
Des complications incluent des troubles du mouvement et des hallucinations.
ComplicationsDopamine
#2
Comment gérer les complications des agents dopaminergiques ?
La gestion implique l'ajustement du dosage et le suivi médical régulier.
Gestion des complicationsDopamine
#3
Les agents dopaminergiques peuvent-ils causer des dépendances ?
Oui, certains agents peuvent entraîner des comportements addictifs chez certains patients.
DépendanceDopamine
#4
Quels sont les risques à long terme des agents dopaminergiques ?
Les risques incluent des mouvements involontaires et une diminution de l'efficacité.
Risques à long termeDopamine
#5
Comment prévenir les complications liées aux agents dopaminergiques ?
Un suivi régulier et une évaluation des symptômes sont essentiels pour prévenir les complications.
PréventionDopamine
Facteurs de risque
5
#1
Quels facteurs augmentent le risque de troubles dopaminergiques ?
L'âge, les antécédents familiaux et certains modes de vie augmentent le risque.
Facteurs de risqueDopamine
#2
Le stress est-il un facteur de risque pour la dopamine ?
Oui, le stress chronique peut perturber l'équilibre de la dopamine dans le cerveau.
StressDopamine
#3
Comment l'alimentation influence-t-elle le risque de troubles dopaminergiques ?
Une alimentation pauvre en nutriments essentiels peut augmenter le risque de troubles dopaminergiques.
NutritionDopamine
#4
Les maladies mentales sont-elles liées à la dopamine ?
Oui, des troubles comme la schizophrénie et la dépression sont souvent liés à des déséquilibres de dopamine.
Maladies mentalesDopamine
#5
L'exposition à des toxines peut-elle affecter la dopamine ?
Oui, certaines toxines environnementales peuvent nuire à la production de dopamine.
ToxinesDopamine
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Agents dopaminergiques : Questions médicales les plus fréquentes",
"headline": "Agents dopaminergiques : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Agents dopaminergiques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-27",
"dateModified": "2026-07-15",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Agents dopaminergiques"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Agents neuromédiateurs",
"url": "https://questionsmedicales.fr/mesh/D018377",
"about": {
"@type": "MedicalCondition",
"name": "Agents neuromédiateurs",
"code": {
"@type": "MedicalCode",
"code": "D018377",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.577"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Agonistes de la dopamine",
"alternateName": "Dopamine Agonists",
"url": "https://questionsmedicales.fr/mesh/D018491",
"about": {
"@type": "MedicalCondition",
"name": "Agonistes de la dopamine",
"code": {
"@type": "MedicalCode",
"code": "D018491",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.577.150.151"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Antagonistes de la dopamine",
"alternateName": "Dopamine Antagonists",
"url": "https://questionsmedicales.fr/mesh/D018492",
"about": {
"@type": "MedicalCondition",
"name": "Antagonistes de la dopamine",
"code": {
"@type": "MedicalCode",
"code": "D018492",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.577.150.175"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Antagonistes du récepteur D2 de la dopamine",
"alternateName": "Dopamine D2 Receptor Antagonists",
"url": "https://questionsmedicales.fr/mesh/D065127",
"about": {
"@type": "MedicalCondition",
"name": "Antagonistes du récepteur D2 de la dopamine",
"code": {
"@type": "MedicalCode",
"code": "D065127",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.577.150.175.500"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Agents dopaminergiques",
"alternateName": "Dopamine Agents",
"code": {
"@type": "MedicalCode",
"code": "D015259",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Richard B Mailman",
"url": "https://questionsmedicales.fr/author/Richard%20B%20Mailman",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA; Department of Neurology, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA; Translational Brain Research Center, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA."
}
},
{
"@type": "Person",
"name": "Yang Yang",
"url": "https://questionsmedicales.fr/author/Yang%20Yang",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA; Translational Brain Research Center, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA. Electronic address: yangyang@psu.edu."
}
},
{
"@type": "Person",
"name": "Mechelle M Lewis",
"url": "https://questionsmedicales.fr/author/Mechelle%20M%20Lewis",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA; Department of Neurology, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA; Translational Brain Research Center, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA."
}
},
{
"@type": "Person",
"name": "Zachary Freyberg",
"url": "https://questionsmedicales.fr/author/Zachary%20Freyberg",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA; Department of Cell Biology, University of Pittsburgh, Pittsburgh, PA 15213, USA. Electronic address: freyberg@pitt.edu."
}
},
{
"@type": "Person",
"name": "Robin A Felder",
"url": "https://questionsmedicales.fr/author/Robin%20A%20Felder",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology, The University of Virginia, Charlottesville, VA, 22904, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen.",
"datePublished": "2024-09-20",
"url": "https://questionsmedicales.fr/article/39372422",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2024.1444010"
}
},
{
"@type": "ScholarlyArticle",
"name": "Informing future randomized controlled trials of amantadine hydrochloride in neurocritical care and post-neurocritical care stroke patients through a retrospective study.",
"datePublished": "2024-09-11",
"url": "https://questionsmedicales.fr/article/39261794",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12883-024-03854-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Subthalamic nucleus-language network connectivity predicts dopaminergic modulation of speech function in Parkinson's disease.",
"datePublished": "2024-05-20",
"url": "https://questionsmedicales.fr/article/38768342",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1073/pnas.2316149121"
}
},
{
"@type": "ScholarlyArticle",
"name": "Treating Malignant Catatonia With Liquid Amantadine: A Case Report and Literature Review.",
"datePublished": "2024-07-01",
"url": "https://questionsmedicales.fr/article/39058531",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/PRA.0000000000000795"
}
},
{
"@type": "ScholarlyArticle",
"name": "Inter-joint coordination with and without dopaminergic medication in Parkinson's disease: a case-control study.",
"datePublished": "2024-07-13",
"url": "https://questionsmedicales.fr/article/39003450",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12984-024-01416-8"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Effets physiologiques des médicaments",
"item": "https://questionsmedicales.fr/mesh/D045505"
},
{
"@type": "ListItem",
"position": 5,
"name": "Agents neuromédiateurs",
"item": "https://questionsmedicales.fr/mesh/D018377"
},
{
"@type": "ListItem",
"position": 6,
"name": "Agents dopaminergiques",
"item": "https://questionsmedicales.fr/mesh/D015259"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Agents dopaminergiques - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Agents dopaminergiques",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-09-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Agents dopaminergiques",
"description": "Comment diagnostiquer un déficit en dopamine ?\nQuels tests sont utilisés pour évaluer la dopamine ?\nQuels symptômes indiquent un traitement dopaminergique ?\nComment évaluer l'efficacité des agents dopaminergiques ?\nQuels médecins prescrivent des agents dopaminergiques ?",
"url": "https://questionsmedicales.fr/mesh/D015259#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Agents dopaminergiques",
"description": "Quels sont les symptômes d'un excès de dopamine ?\nComment la dopamine affecte-t-elle l'humeur ?\nQuels troubles sont liés à un déficit de dopamine ?\nQuels symptômes sont traités par des agents dopaminergiques ?\nComment la dopamine influence-t-elle la motivation ?",
"url": "https://questionsmedicales.fr/mesh/D015259#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Agents dopaminergiques",
"description": "Peut-on prévenir les troubles liés à la dopamine ?\nQuels modes de vie favorisent la santé de la dopamine ?\nY a-t-il des aliments qui augmentent la dopamine ?\nComment le stress affecte-t-il la dopamine ?\nLes suppléments peuvent-ils aider la dopamine ?",
"url": "https://questionsmedicales.fr/mesh/D015259#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Agents dopaminergiques",
"description": "Quels sont les principaux agents dopaminergiques ?\nComment les agents dopaminergiques sont-ils administrés ?\nQuels effets secondaires des agents dopaminergiques ?\nComment ajuster le dosage des agents dopaminergiques ?\nLes agents dopaminergiques sont-ils efficaces pour tous ?",
"url": "https://questionsmedicales.fr/mesh/D015259#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Agents dopaminergiques",
"description": "Quelles complications peuvent survenir avec les agents dopaminergiques ?\nComment gérer les complications des agents dopaminergiques ?\nLes agents dopaminergiques peuvent-ils causer des dépendances ?\nQuels sont les risques à long terme des agents dopaminergiques ?\nComment prévenir les complications liées aux agents dopaminergiques ?",
"url": "https://questionsmedicales.fr/mesh/D015259#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Agents dopaminergiques",
"description": "Quels facteurs augmentent le risque de troubles dopaminergiques ?\nLe stress est-il un facteur de risque pour la dopamine ?\nComment l'alimentation influence-t-elle le risque de troubles dopaminergiques ?\nLes maladies mentales sont-elles liées à la dopamine ?\nL'exposition à des toxines peut-elle affecter la dopamine ?",
"url": "https://questionsmedicales.fr/mesh/D015259#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un déficit en dopamine ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'évaluation des symptômes cliniques et des tests neurologiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la dopamine ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'imagerie cérébrale et des analyses de sang peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un traitement dopaminergique ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent la rigidité musculaire, les tremblements et la bradykinésie."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité des agents dopaminergiques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par l'amélioration des symptômes cliniques et des tests fonctionnels."
}
},
{
"@type": "Question",
"name": "Quels médecins prescrivent des agents dopaminergiques ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les neurologues et psychiatres sont les principaux prescripteurs de ces médicaments."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'un excès de dopamine ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent l'anxiété, l'agitation, et des comportements compulsifs."
}
},
{
"@type": "Question",
"name": "Comment la dopamine affecte-t-elle l'humeur ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "La dopamine joue un rôle clé dans la régulation de l'humeur et des émotions."
}
},
{
"@type": "Question",
"name": "Quels troubles sont liés à un déficit de dopamine ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le Parkinson et la dépression sont des troubles souvent associés à un déficit de dopamine."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont traités par des agents dopaminergiques ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils traitent des symptômes comme les tremblements, la rigidité et la dépression."
}
},
{
"@type": "Question",
"name": "Comment la dopamine influence-t-elle la motivation ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "La dopamine est impliquée dans le circuit de la récompense, influençant la motivation."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés à la dopamine ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et l'exercice peuvent aider à maintenir un bon équilibre dopaminergique."
}
},
{
"@type": "Question",
"name": "Quels modes de vie favorisent la santé de la dopamine ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un sommeil adéquat, la gestion du stress et l'exercice régulier favorisent la santé dopaminergique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des aliments qui augmentent la dopamine ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les aliments riches en tyrosine, comme les bananes et les avocats, peuvent aider."
}
},
{
"@type": "Question",
"name": "Comment le stress affecte-t-il la dopamine ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut réduire les niveaux de dopamine et affecter l'humeur."
}
},
{
"@type": "Question",
"name": "Les suppléments peuvent-ils aider la dopamine ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains suppléments, comme la L-tyrosine, peuvent soutenir la production de dopamine."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux agents dopaminergiques ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les agonistes de la dopamine comme la cabergoline et la bromocriptine sont courants."
}
},
{
"@type": "Question",
"name": "Comment les agents dopaminergiques sont-ils administrés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être administrés par voie orale, injectable ou transdermique."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires des agents dopaminergiques ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent nausées, vertiges et troubles du sommeil."
}
},
{
"@type": "Question",
"name": "Comment ajuster le dosage des agents dopaminergiques ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le dosage est ajusté en fonction de la réponse clinique et des effets secondaires."
}
},
{
"@type": "Question",
"name": "Les agents dopaminergiques sont-ils efficaces pour tous ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité varie selon les individus et les conditions traitées."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les agents dopaminergiques ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles du mouvement et des hallucinations."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications des agents dopaminergiques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique l'ajustement du dosage et le suivi médical régulier."
}
},
{
"@type": "Question",
"name": "Les agents dopaminergiques peuvent-ils causer des dépendances ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains agents peuvent entraîner des comportements addictifs chez certains patients."
}
},
{
"@type": "Question",
"name": "Quels sont les risques à long terme des agents dopaminergiques ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des mouvements involontaires et une diminution de l'efficacité."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications liées aux agents dopaminergiques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier et une évaluation des symptômes sont essentiels pour prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de troubles dopaminergiques ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge, les antécédents familiaux et certains modes de vie augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque pour la dopamine ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut perturber l'équilibre de la dopamine dans le cerveau."
}
},
{
"@type": "Question",
"name": "Comment l'alimentation influence-t-elle le risque de troubles dopaminergiques ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation pauvre en nutriments essentiels peut augmenter le risque de troubles dopaminergiques."
}
},
{
"@type": "Question",
"name": "Les maladies mentales sont-elles liées à la dopamine ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles comme la schizophrénie et la dépression sont souvent liés à des déséquilibres de dopamine."
}
},
{
"@type": "Question",
"name": "L'exposition à des toxines peut-elle affecter la dopamine ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines toxines environnementales peuvent nuire à la production de dopamine."
}
}
]
}
]
}
Department of Pharmacology, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA; Department of Neurology, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA; Translational Brain Research Center, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA.
Department of Pharmacology, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA; Translational Brain Research Center, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA. Electronic address: yangyang@psu.edu.
Department of Pharmacology, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA; Department of Neurology, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA; Translational Brain Research Center, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA.
Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA; Department of Cell Biology, University of Pittsburgh, Pittsburgh, PA 15213, USA. Electronic address: freyberg@pitt.edu.
Schwartz, PharmD, BCPP, Assistant Professor of Clinical Sciences; Pullen, Graduate Student Researcher; Bernard, Graduate Student Researcher, High Point University Fred Wilson School of Pharmacy, One University Parkway, High Point. Dinkla, Undergraduate Student Researcher, High Point University Congdon School of Health Sciences, One University Parkway, High Point. Kumar, MD, Medical Director and Chief of Psychiatry, Cone Health Behavioral Health Hospital, Greensboro.
Schwartz, PharmD, BCPP, Assistant Professor of Clinical Sciences; Pullen, Graduate Student Researcher; Bernard, Graduate Student Researcher, High Point University Fred Wilson School of Pharmacy, One University Parkway, High Point. Dinkla, Undergraduate Student Researcher, High Point University Congdon School of Health Sciences, One University Parkway, High Point. Kumar, MD, Medical Director and Chief of Psychiatry, Cone Health Behavioral Health Hospital, Greensboro.
Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program , National Institutes of Health , 333 Cassell Drive , Baltimore , Maryland 21224 , United States.
Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program , National Institutes of Health , 333 Cassell Drive , Baltimore , Maryland 21224 , United States.
Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke-Intramural Research Program , National Institutes of Health , Bethesda , Maryland 20892 , United States.
Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, 21224, USA. zxi@mail.nih.gov.
Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, 21224, USA. amy.newman@nih.gov.
We report on a patient with ciltacabtagene autoleucel-induced movement and neurocognitive toxicity, which was refractory to immunosuppression but responsive to combination dopaminergic therapy (carbid...
Amantadine hydrochloride has been increasingly prescribed as a neurostimulant for neurocritical care stroke patients to promote wakefulness during inpatient recovery. However, a lack of guidelines mak...
Retrospective chart review for this study included neurocritical care and post-neurocritical care patients with acute ischemic or hemorrhagic stroke who were started on amantadine (N = 34) in the year...
There were large but nonsignificant variations in the median total milligrams of amantadine received in the first 9 days (IQR = 700-1,450 mg, p = 0.727). GCS on the day before amantadine initiation wa...
Future randomized controlled trials of amantadine in hospitalized stroke patients should possibly consider examining dose-dependent relationships to establish stroke-specific dosing guidelines, minimu...
Speech impediments are a prominent yet understudied symptom of Parkinson's disease (PD). While the subthalamic nucleus (STN) is an established clinical target for treating motor symptoms, these interv...
Malignant catatonia (MC) is a complex, life-threatening condition characterized by motor dysregulation and autonomic instability, which requires prompt and effective treatment. There are some limitati...
How the joints exactly move and interact and how this reflects PD-related gait abnormalities and the response to dopaminergic treatment is poorly understood. A detailed understanding of these kinemati...
29 controls and 29 PD patients during medication on, 8 of them also during medication off walked a straight walking path in slow, preferred and fast walking speeds. Gait data was collected using optic...
PD gait differed from controls mainly by lower knee range of motion (ROM). Adaptation to gait speed in PD was mainly achieved by increasing hip ROM. Regularity of gait was worse in PD but only during ...
Our findings demonstrate the potential of granular kinematic analyses, including > 1 joint, for disease and treatment monitoring in PD. Our approach can be extended to further mobility-limiting condit...
The study is registered in the German Clinical Trials Register (DRKS00022998, registered on 04 Sep 2020)....
In Parkinson's disease, safinamide and zonisamide are novel monoamine oxidase-B inhibitors with a dual mechanism of action involving the inhibition of sodium and calcium channels and the subsequent re...
We searched MEDLINE, EMBASE, Cochrane Central, Scopus, PsycINFO, and trials registries up to March 2023 for randomized controlled trials of adults with Parkinson's disease administered either safinami...
Of 3570 screened citations, 16 trials met inclusion criteria (4314 patients with Parkinson's disease). Ten safinamide trials were conducted in several countries. Six zonisamide trials were included, f...
Evidence suggests that novel monoamine oxidase-B inhibitors not only improve motor symptoms but also enhance patients' quality of life. The meta-analysis showed that both medications have a similar sa...
Monoamine oxidase B (MAO-B) inhibitors are used to control Parkinson's disease (PD). Selegiline, rasagiline, and safinamide are widely used as MAO-B inhibitors worldwide. Although these drugs inhibit ...
Augmentation of restless legs syndrome (RLS) is an iatrogenic side effect induced by dopaminergic agents, and it is a major cause of therapeutic failure. Iron deficiency is a risk factor for RLS, but ...
We searched the PubMed, Cochrane Library, Embase, ClinicalKey, ScienceDirect, and ProQuest databases for studies comparing the serum ferritin levels of patients with augmented RLS and nonaugmented RLS...
Six observational studies fulfilled the eligibility criteria of this meta-analysis. A total of 220 RLS patients with augmentation and 687 RLS patients without augmentation were included. The results r...
A low serum ferritin level is associated with RLS augmentation. For patients with RLS who are iron deficient, iron supplements can not only relieve their fundamental RLS symptoms but also lower the ri...
The dopamine transporter has a crucial role in regulation of dopaminergic neurotransmission by uptake of dopamine into neurons and contributes to the abuse potential of psychomotor stimulants...
Dopamine, a frequently used therapeutic agent for critically ill patients, has been shown to be implicated in clinical infections recently, however, the precise mechanisms underlying this association ...
Considering the contribution of host immune factors during infection, this study aimed to investigate the intricate interactions between...
RAW264.7 cells and C57/BL6 mice were infected with...
Dopamine inhibited the growth of...
Our findings suggest that dopamine may be one of the potential risk factors associated with...